Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
Pharmaceutical Fronts · 01.12.2025 · 07 (04) · e275-e293
DOI: 10.1055/a-2742-7859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.12.2025. Verfasst von Xing Tian und 4 weiteren Autor:innen. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liaoning Innovative Talents in University.
Abstract (Originalsprache)
Targeting cyclin-dependent kinase (CDK) families is a promising strategy for cancer therapy due to the close association between CDKs and an abnormal cell cycle or transcriptional regulation. However, after extensive clinical use, small molecule inhibitors of CDKs have also exposed issues, such as off-target effects or acquired drug resistance. Targeting protein degradation technology, which has been validated to be effective for many targets, has undergone more than 20 years of development, and some of these methods have been pushed into clinical trials. In this review, we summarized some successful reports on CDK-targeted degradation during recent years. Moreover, some challenging issues and future development trends are highlighted in the prospect section, which might provide updated insight into the development of novel CDK-targeted degraders with great potential as a new weapon for cancer therapy.
Förderung
- Liaoning Innovative Talents in University
Zitieren
APA
Tian, X., Dai, X., Zhong, Y., Cheng, M., & Liu, Y. (2025). Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy. Pharmaceutical Fronts, 07(04), e275-e293. https://doi.org/10.1055/a-2742-7859
Vancouver
Tian X, Dai X, Zhong Y, Cheng M, Liu Y. Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy. Pharmaceutical Fronts. 2025;07(04):e275-e293. doi:10.1055/a-2742-7859
BibTeX
@article{Tian2025,
author = {Tian, Xing and Dai, Xiaojie and Zhong, Ye and Cheng, Maosheng and Liu, Yang},
title = {Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy},
journal = {Pharmaceutical Fronts},
year = {2025},
volume = {07},
number = {04},
pages = {e275--e293},
doi = {10.1055/a-2742-7859}
}
EUVIMED